YTHDF2 inhibition potentiates radiotherapy antitumor efficacy

References 92

1. 1.

   Liauw SL, Connell PP, and Weichselbaum RR (2013 ). New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology. Science Translational Medicine 5, 173sr2.

   Not in our library10.1126/scitranslmed.3005148 (opens in a new tab)

2. 2.

   Weichselbaum RR, Liang H, Deng LF, and Fu YX (2017 ). Radiotherapy and immunotherapy: a beneficial liaison? Nature Reviews Clinical Oncology 14, 365–379.

   Not in our library10.1038/nrclinonc.2016.211 (opens in a new tab)

3. 3.
   Cancer Stem Cells and Radioresistance: DNA Repair and Beyond · 2019

   No notice
4. 4.

   Fridman WH, Zitvogel L, Sautes-Fridman C, and Kroemer G (2017 ). The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14, 717–734.

   Not in our library10.1038/nrclinonc.2017.101 (opens in a new tab)

5. 5.

   Brandmaier A, and Formenti SC (2020 ). The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity. Semin Radiat Oncol 30, 139–144.

   Not in our library10.1016/j.semradonc.2019.12.005 (opens in a new tab)

6. 6.

   Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, and Auh SL (2011 ). The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71, 2488–2496.

   Not in our library10.1158/0008-5472.can-10-2820 (opens in a new tab)

7. 7.

   Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, (2018 ). Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24, 1845–1851.

   Not in our library10.1038/s41591-018-0232-2 (opens in a new tab)

8. 8.

   Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, (2009 ). Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114, 589–595.

   Not in our library10.1182/blood-2009-02-206870 (opens in a new tab)

9. 9.

   Searle EJ, Telfer BA, Mukherjee D, Forster DM, Davies BR, Williams KJ, Stratford IJ, and Illidge TM (2017 ). Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment. EMBO Mol Med 9, 1646–1659.

   Not in our library10.15252/emmm.201707767 (opens in a new tab)

10. 10.

    Pointer KB, Pitroda SP, and Weichselbaum RR (2022 ). Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer 8, 9–20.

    Not in our library10.1016/j.trecan.2021.10.003 (opens in a new tab)

11. 11.

    Turchan WT, Pitroda SP, and Weichselbaum RR (2021 ). Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res 27, 5188–5194.

    Not in our library10.1158/1078-0432.ccr-21-0145 (opens in a new tab)

12. 12.

    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, (2017 ). Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 377, 1919–1929.

    Not in our library10.1056/nejmoa1709937 (opens in a new tab)

13. 13.

    Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lievre A, (2021 ). Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 384, 1191–1203.

    Not in our library10.1056/nejmoa2032125 (opens in a new tab)

14. 14.

    Bang A, and Schoenfeld JD (2019 ). Immunotherapy and radiotherapy for metastatic cancers. Ann Palliat Med 8, 312–325.

    Not in our library10.21037/apm.2018.07.10 (opens in a new tab)

15. 15.

    Colton M, Cheadle EJ, Honeychurch J, and Illidge TM (2020 ). Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiat Oncol 15, 254.

    Not in our library10.1186/s13014-020-01678-1 (opens in a new tab)

16. 16.

    Gabrilovich DI, and Nagaraj S (2009 ). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162–174.

    Not in our library10.1038/nri2506 (opens in a new tab)

17. 17.

    Zhao JL, Ye YC, Gao CC, Wang L, Ren KX, Jiang R, Hu SJ, Liang SQ, Bai J, Liang JL, (2022 ). Notch-mediated lactate metabolism regulates MDSC development through the Hes1/MCT2/c-Jun axis. Cell Rep 38, 110451.

    Not in our library10.1016/j.celrep.2022.110451 (opens in a new tab)

18. 18.

    Engblom C, Pfirschke C, and Pittet MJ (2016 ). The role of myeloid cells in cancer therapies. Nat Rev Cancer 16, 447–462.

    Not in our library10.1038/nrc.2016.54 (opens in a new tab)

19. 19.

    Jimenez-Cortegana C, Galassi C, Klapp V, Gabrilovich DI, and Galluzzi L (2022 ). Myeloid-Derived Suppressor Cells and Radiotherapy. Cancer Immunol Res 10, 545–557.

    Not in our library10.1158/2326-6066.cir-21-1105 (opens in a new tab)

20. 20.

    Barker HE, Paget JTE, Khan AA, and Harrington KJ (2015 ). The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nature Reviews Cancer 15, 409–425.

    Not in our library10.1038/nrc3958 (opens in a new tab)

21. 21.

    Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng WG, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, (2015 ). The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine 21, 938–945.

    Not in our library10.1038/nm.3909 (opens in a new tab)

22. 22.

    Haughey CM, Mukherjee D, Steele RE, Popple A, Dura-Perez L, Pickard A, Patel M, Jain S, Mullan PB, Williams R, (2020 ). Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. Cancers (Basel) 12, 2804.

    Not in our library10.3390/cancers12102804 (opens in a new tab)

23. 23.

    Lin L, Kane N, Kobayashi N, Kono EA, Yamashiro JM, Nickols NG, and Reiter RE (2021 ). High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. Clin Cancer Res 27, 1505–1515.

    Not in our library10.1158/1078-0432.ccr-20-2293 (opens in a new tab)

24. 24.

    Oweida AJ, Mueller AC, Piper M, Milner D, Van Court B, Bhatia S, Phan A, Bickett T, Jordan K, Proia T, (2021 ). Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. Cancer Immunol Immunother 70, 989–1000.

    Not in our library10.1007/s00262-020-02701-w (opens in a new tab)

25. 25.

    Ghosh S, Huang J, Inkman M, Zhang J, Thotala S, Tikhonova E, Miheecheva N, Frenkel F, Ataullakhanov R, Wang X, (2023 ). Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. Sci Transl Med 15, eabn6758.

    Not in our library10.1126/scitranslmed.abn6758 (opens in a new tab)

26. 26.
    Host STING-dependent MDSC mobilization drives extrinsic radiation resistance · 2017

    No notice
27. 27.

    Fu SY, Chen FH, Wang CC, Yu CF, Chiang CS, and Hong JH (2021 ). Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment. Radiat Oncol Biol Phys 109, 1547–1558.

    Not in our library10.1016/j.ijrobp.2020.11.004 (opens in a new tab)

28. 28.

    Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, (2016 ). Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer 115, 252–260.

    Not in our library10.1038/bjc.2016.166 (opens in a new tab)

29. 29.

    Tsai MS, Chen WC, Lai CH, Chen YY, and Chen MF (2017 ). Epigenetic therapy regulates the expression of ALDH1 and immunologic response: Relevance to the prognosis of oral cancer. Oral Oncol 73, 88–96.

    Not in our library10.1016/j.oraloncology.2017.08.007 (opens in a new tab)

30. 30.
    Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients · 2017

    No notice
31. 31.

    Talebian Yazdi M, Schinkelshoek MS, Loof NM, Taube C, Hiemstra PS, Welters MJ, and van der Burg SH (2016 ). Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer. Oncoimmunology 5, e1255393.

    Not in our library10.1080/2162402x.2016.1255393 (opens in a new tab)

32. 32.

    Wang D, An G, Xie S, Yao Y, and Feng G (2016 ). The clinical and prognostic significance of CD14(+)HLA-DR(−/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. Tumour Biol 37, 10427–10433.

    Not in our library10.1007/s13277-016-4916-2 (opens in a new tab)

33. 33.

    Tsai MS, Chen WC, Lu CH, and Chen MF (2019 ). The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling. Oral Oncol 91, 47–55.

    Not in our library10.1016/j.oraloncology.2019.02.027 (opens in a new tab)

34. 34.
    Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer · 2020

    No notice
35. 35.

    Ko JS, Zea AH, Rin BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, (2009 ). Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients. Clinical Cancer Research 15, 2148–2157.

    Not in our library10.1158/1078-0432.ccr-08-1332 (opens in a new tab)

36. 36.

    Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, (2016 ). Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell 29, 587–601.

    Not in our library10.1016/j.ccell.2016.03.005 (opens in a new tab)

37. 37.

    Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, (2015 ). Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 21, 30–38.

    Not in our library10.1158/1078-0432.ccr-14-1716 (opens in a new tab)

38. 38.

    Iclozan C, Antonia S, Chiappori A, Chen DT, and Gabrilovich D (2013 ). Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunology Immunotherapy 62, 909–918.

    Not in our library10.1007/s00262-013-1396-8 (opens in a new tab)

39. 39.

    Frye M, Harada BT, Behm M, and He C (2018 ). RNA modifications modulate gene expression during development. Science 361, 1346–1349.

    Not in our library10.1126/science.aau1646 (opens in a new tab)

40. 40.

    Wang X, and He C (2014 ). Dynamic RNA Modifications in Posttranscriptional Regulation. Molecular Cell 56, 5–12.

    Not in our library10.1016/j.molcel.2014.09.001 (opens in a new tab)

Cited by papers we hold 3

• Phosphorus-32 microspheres: A dual-modality transarterial radioembolization approach for hepatocellular carcinoma therapy and Anti-PD1 immunotherapy potentiation · 2025
  Not checked
• The role of RNA methylation in tumor immunity and its potential in immunotherapy · 2024
  No notice
• Epigenetics-targeted drugs: current paradigms and future challenges · 2024
  No notice

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.